|
SG168422A1
(en)
|
2001-11-13 |
2011-02-28 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
JP4810062B2
(ja)
|
2001-12-17 |
2011-11-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アデノ随伴ウイルス（ａａｖ）血清型８の配列
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
EP3910063A1
(en)
*
|
2003-09-30 |
2021-11-17 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
ES2361000T3
(es)
|
2004-04-28 |
2011-06-13 |
The Trustees Of The University Of Pennsylvania |
Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado.
|
|
JP2007535541A
(ja)
|
2004-04-28 |
2007-12-06 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｅ４欠失アデノウイルス初回免疫およびｅ１欠失アデノウイルス追加免疫を用いる免疫化方式
|
|
EP3409296A1
(en)
|
2005-04-07 |
2018-12-05 |
The Trustees of the University of Pennsylvania |
Method of increasing the function of an aav vector
|
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
|
AU2007234698B2
(en)
*
|
2006-04-07 |
2013-08-01 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
|
CN101495624A
(zh)
*
|
2006-04-28 |
2009-07-29 |
宾夕法尼亚州立大学托管会 |
衣壳免疫原性降低的经修饰aav载体及其用途
|
|
JP5268890B2
(ja)
|
2006-04-28 |
2013-08-21 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ａａｖの規模適応性の製造方法
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
EP3492596A1
(en)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
|
EP2019143A1
(en)
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
|
US8632764B2
(en)
*
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
WO2010093784A2
(en)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
ES2724122T3
(es)
|
2009-04-30 |
2019-09-06 |
Univ Pennsylvania |
Composiciones para dirigir células de las vías respiratorias de conducción que comprenden construcciones de virus adenoasociado
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
WO2010141706A1
(en)
*
|
2009-06-03 |
2010-12-09 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
|
WO2011041502A1
(en)
|
2009-10-01 |
2011-04-07 |
The Trustees Of The University Of Pennsylvania |
Aav vectors expressing sec1o for treating kidney damage
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3540055A1
(en)
|
2010-04-23 |
2019-09-18 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US9272053B2
(en)
|
2010-04-23 |
2016-03-01 |
University Of Massachusetts |
AAV-based treatment of cholesterol-related disorders
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
EP2634253B1
(en)
|
2010-10-27 |
2016-05-11 |
Jichi Medical University |
Adeno-associated virus virions for transferring genes into neural cells
|
|
JP6042825B2
(ja)
*
|
2011-02-10 |
2016-12-14 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
|
|
SG10202007803QA
(en)
|
2011-02-17 |
2020-09-29 |
Univ Pennsylvania |
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
|
|
EP2699688A1
(en)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
LT3254703T
(lt)
|
2011-04-22 |
2020-05-25 |
The Regents Of The University Of California |
Adenoasocijuoto viruso virionai su variantine kapside ir jų panaudojimo būdai
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
EP2748185A1
(en)
*
|
2011-08-24 |
2014-07-02 |
The Board of Trustees of The Leland Stanford Junior University |
New aav capsid proteins for nucleic acid transfer
|
|
US8859256B2
(en)
|
2011-10-05 |
2014-10-14 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
WO2013063019A1
(en)
|
2011-10-28 |
2013-05-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
|
|
US10238755B2
(en)
|
2011-11-30 |
2019-03-26 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
|
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
|
WO2013103896A1
(en)
*
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
|
JP6385920B2
(ja)
|
2012-05-09 |
2018-09-05 |
オレゴン ヘルス アンド サイエンス ユニバーシティー |
アデノ随伴ウイルスプラスミド及びベクター
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
JP6199965B2
(ja)
|
2012-07-11 |
2017-09-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療
|
|
PT2879719T
(pt)
|
2012-08-01 |
2018-10-08 |
Ohio State Innovation Foundation |
Administração intratecal do vírus adeno-associado 9 recombinante
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
EP3738974A1
(en)
*
|
2012-09-28 |
2020-11-18 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
|
CA2905952A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
|
JP6628285B2
(ja)
|
2013-03-14 |
2020-01-08 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
Ａｌｓ関連ジアミノ酸リピート含有タンパク質
|
|
JP6591956B2
(ja)
|
2013-03-15 |
2019-10-16 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｍｐｓ１を治療するための組成物および方法
|
|
IL293294B2
(en)
*
|
2013-03-15 |
2023-04-01 |
Univ North Carolina Chapel Hill |
Methods and compounds for ligation of paired aav glycan vectors
|
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
|
WO2014194132A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
EP3633041A3
(en)
|
2013-09-26 |
2020-07-29 |
University of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
EP3054995A1
(en)
*
|
2013-10-07 |
2016-08-17 |
Kiromic, LLC |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
|
NZ758025A
(en)
*
|
2013-10-11 |
2022-07-01 |
Massachusetts Eye & Ear Infirmary |
Methods of predicting ancestral virus sequences and uses thereof
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
SI3116900T1
(sl)
|
2014-03-09 |
2021-02-26 |
The Trustees Of The University Of Pennsylvania |
Sestavki uporabni pri zdravljenju pomanjkanja ornitin transkarbamilaze(OTC)
|
|
ES2990174T3
(es)
|
2014-03-10 |
2024-11-29 |
Uniqure Ip Bv |
Vectores de AAV mejorados producidos en células de insecto
|
|
CA2942776C
(en)
|
2014-03-17 |
2023-01-24 |
Adverum Biotechnologies, Inc. |
Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
|
|
JP6756700B2
(ja)
|
2014-03-18 |
2020-09-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症を処置するためのｒＡＡＶベースの組成物および方法
|
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
|
JP6983511B2
(ja)
|
2014-04-25 |
2021-12-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
脳中の転移乳癌および他の癌を処置するための方法および組成物
|
|
WO2015164778A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennysylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
ES2833230T3
(es)
|
2014-05-13 |
2021-06-14 |
Univ Pennsylvania |
Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
|
EP3800260A1
(en)
|
2014-09-24 |
2021-04-07 |
City of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるａａｖベクター
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
KR102122463B1
(ko)
|
2014-10-14 |
2020-06-15 |
할로자임, 아이엔씨 |
아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
|
|
RU2738421C2
(ru)
|
2014-10-21 |
2020-12-14 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
KR20170096998A
(ko)
|
2014-11-05 |
2017-08-25 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드
|
|
AU2015342997B2
(en)
*
|
2014-11-05 |
2021-11-18 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
WO2016077689A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
AU2015349759B2
(en)
|
2014-11-21 |
2022-01-06 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
EP3233131A1
(en)
|
2014-12-16 |
2017-10-25 |
Board of Regents of the University of Nebraska |
Gene therapy for juvenile batten disease
|
|
EP3242945B1
(en)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
CA2972811A1
(en)
|
2015-01-16 |
2016-07-21 |
University Of Washington |
Novel micro-dystrophins and related methods of use
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
KR20170137730A
(ko)
|
2015-03-02 |
2017-12-13 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
|
|
WO2016145217A1
(en)
|
2015-03-10 |
2016-09-15 |
The Trustees Of Columbia University In The City Of New York |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
|
|
WO2016154344A1
(en)
*
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
US20180110877A1
(en)
|
2015-04-27 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE
|
|
AU2016256894B2
(en)
|
2015-05-07 |
2020-11-26 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
CA2985786A1
(en)
*
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
|
EP3307310A2
(en)
|
2015-05-13 |
2018-04-18 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-influenza antibodies and methods of use thereof
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
WO2016196324A1
(en)
|
2015-05-29 |
2016-12-08 |
University Of Floridia Research Foundation, Inc. |
Methods for diagnosing huntington's disease
|
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
CA2994160C
(en)
*
|
2015-07-30 |
2021-08-10 |
Massachusetts Eye And Ear Infirmary |
Ancestral virus sequences and uses thereof
|
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
HK1256909A1
(zh)
|
2015-08-06 |
2019-10-04 |
宾夕法尼亚大学 |
Glp-1和其在用於治疗代谢疾病的组合物中的用途
|
|
KR102699944B1
(ko)
|
2015-08-25 |
2024-09-13 |
듀크 유니버시티 |
Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법
|
|
CN108137664B
(zh)
|
2015-08-31 |
2021-11-26 |
宾夕法尼亚州大学信托人 |
用于治疗伴侣动物的aav-epo
|
|
AU2016326627B2
(en)
|
2015-09-24 |
2022-12-15 |
The Trustees Of The University Of Pennsylvania |
Composition and method for treating complement-mediated disease
|
|
PT3356390T
(pt)
|
2015-09-28 |
2021-04-21 |
Univ Florida |
Métodos e composições para vetores virais que se evadem a anticorpos
|
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
WO2017066764A2
(en)
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
US12188037B2
(en)
*
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
WO2017070516A1
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
EP3368563A1
(en)
|
2015-10-28 |
2018-09-05 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
WO2017077451A1
(en)
|
2015-11-05 |
2017-05-11 |
Bamboo Therapeutics, Inc. |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
WO2017100671A1
(en)
*
|
2015-12-11 |
2017-06-15 |
California Institute Of Technology |
TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
CN115957350A
(zh)
|
2015-12-11 |
2023-04-14 |
宾夕法尼亚州大学信托人 |
用于治疗家族性高胆固醇血症的基因疗法
|
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
|
WO2017100791A1
(en)
|
2015-12-11 |
2017-06-15 |
Massachusetts Eye And Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
|
WO2017106354A1
(en)
*
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
|
RU2762747C2
(ru)
|
2015-12-14 |
2021-12-22 |
Зе Трастис Оф Зе Юниверсити Оф Пенсильвания |
Генная терапия офтальмологических нарушений
|
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
EP3411488A1
(en)
|
2016-02-03 |
2018-12-12 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
HRP20231451T1
(hr)
|
2016-02-05 |
2024-03-01 |
Emory University |
Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
EP3440100A4
(en)
|
2016-04-04 |
2020-01-22 |
University of Florida Research Foundation, Incorporated |
HANDLING EIF3 TO MODULATE A NON-ATG TRANSLATION ASSOCIATED WITH A REPETITION (RAN)
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
WO2017180936A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
WO2017181148A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Icos ligand variant immunomodulatory proteins and uses thereof
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11091776B2
(en)
*
|
2016-04-15 |
2021-08-17 |
The Trustees Of The University Of Pennsylvania |
AAV8 mutant capsids and compositions containing same
|
|
KR102450833B1
(ko)
|
2016-04-15 |
2022-10-05 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
혈우병 a 치료용 유전자 요법
|
|
IL305449B1
(en)
|
2016-04-15 |
2025-09-01 |
Univ Pennsylvania |
Gene therapy for the treatment of mucocutaneous type ii diabetes
|
|
IL310729A
(en)
|
2016-04-15 |
2024-04-01 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3452495B1
(en)
*
|
2016-05-03 |
2021-06-23 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
|
MX2018013463A
(es)
|
2016-05-13 |
2019-07-04 |
4D Molecular Therapeutics Inc |
Capsides variantes de virus adenoasociados y metodos de uso de las mismas.
|
|
CA3024448C
(en)
|
2016-05-18 |
2025-09-09 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics Inc |
composições e métodos de tratamento da doença de huntington
|
|
EP3469080A4
(en)
|
2016-06-13 |
2020-01-22 |
The University of North Carolina at Chapel Hill |
OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
CN110191954B
(zh)
|
2016-07-08 |
2024-05-14 |
宾夕法尼亚州大学信托人 |
用于治疗涉及rdh12的病症和疾病的方法和组合物
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
EP3491008A2
(en)
|
2016-07-26 |
2019-06-05 |
BioMarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
KR20230039779A
(ko)
|
2016-07-29 |
2023-03-21 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
|
|
WO2018035503A1
(en)
|
2016-08-18 |
2018-02-22 |
The Regents Of The University Of California |
Crispr-cas genome engineering via a modular aav delivery system
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
|
CA3041068A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
EP3528785A4
(en)
|
2016-10-19 |
2020-12-02 |
Adverum Biotechnologies, Inc. |
MODIFIED AAV CASPIDS AND USES THEREOF
|
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
US20180245065A1
(en)
|
2016-11-01 |
2018-08-30 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
EP3548065B1
(en)
|
2016-12-01 |
2022-11-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
MX2019007876A
(es)
|
2016-12-30 |
2019-10-15 |
Univ Pennsylvania |
Terapia genetica para tratar fenilcetonuria.
|
|
MX2019007873A
(es)
|
2016-12-30 |
2019-11-18 |
Univ Pennsylvania |
Terapia génica para tratar la enfermedad de wilson.
|
|
EP3570895A1
(en)
|
2017-01-17 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
|
EP3576760A2
(en)
|
2017-02-01 |
2019-12-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
|
EP3580341A4
(en)
|
2017-02-09 |
2020-11-04 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and compositions and methods thereof
|
|
US11554147B2
(en)
|
2017-02-20 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
WO2018156654A1
(en)
|
2017-02-21 |
2018-08-30 |
University Of Florida Research Foundation, Incorporated |
Modified aav capsid proteins and uses thereof
|
|
EP3655533A1
(en)
|
2017-02-24 |
2020-05-27 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
|
AU2018229293A1
(en)
|
2017-02-28 |
2019-08-29 |
Janssen Biotech, Inc. |
Influenza vaccines based on AAV vectors
|
|
US11827906B2
(en)
*
|
2017-02-28 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clade f vector and uses therefor
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
KR20230093072A
(ko)
|
2017-03-01 |
2023-06-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
안구 장애에 대한 유전자 치료
|
|
US11376321B2
(en)
|
2017-03-02 |
2022-07-05 |
Genethon |
Method for removing anti-AAV antibodies from a blood-derived composition
|
|
WO2018170021A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
US11732022B2
(en)
|
2017-03-16 |
2023-08-22 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
IL268781B2
(en)
|
2017-03-16 |
2025-09-01 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
IL269472B2
(en)
|
2017-03-24 |
2024-10-01 |
Lankenau Inst Medical Res |
Methods and preparations for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
|
CN118813559A
(zh)
|
2017-03-31 |
2024-10-22 |
北京三诺佳邑生物技术有限责任公司 |
shRNA表达框、携带其的多核苷酸序列及其应用
|
|
WO2018189208A1
(en)
|
2017-04-10 |
2018-10-18 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
US11613739B2
(en)
|
2017-04-14 |
2023-03-28 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells
|
|
US11345911B2
(en)
*
|
2017-04-17 |
2022-05-31 |
University Of Florida Research Foundation, Incorporated |
Regulation of RAN translation by PKR and eIF2A-P pathways
|
|
EP3634986A4
(en)
|
2017-04-24 |
2021-09-08 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR EYE DISORDERS
|
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
CA3061655A1
(en)
|
2017-05-11 |
2018-11-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
EP3630986A4
(en)
|
2017-05-31 |
2021-08-11 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR TREATMENT OF PEROXISOMAL DISEASES
|
|
JP7766393B2
(ja)
|
2017-06-14 |
2025-11-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
JP2020530307A
(ja)
*
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス，インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
|
CN110461368A
(zh)
|
2017-06-30 |
2019-11-15 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
AU2018298133A1
(en)
|
2017-07-06 |
2020-01-23 |
The Trustees Of The University Of Pennsylvania |
AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
|
|
WO2019008157A1
(en)
|
2017-07-07 |
2019-01-10 |
Genethon |
NOVEL POLYNUCLEOTIDES ENCODING HUMAN FKRP PROTEIN
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
JP2020530986A
(ja)
|
2017-07-27 |
2020-11-05 |
ノバルティス アーゲー |
シェダーゼ耐性ｔｒｅｍ２変異体
|
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3676373A4
(en)
|
2017-08-28 |
2021-06-09 |
The Regents of The University of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
DK3684423T5
(da)
|
2017-09-20 |
2024-08-26 |
4D Molecular Therapeutics Inc |
Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
|
|
SG11202002457RA
(en)
|
2017-09-22 |
2020-04-29 |
Univ Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
WO2019060686A1
(en)
|
2017-09-22 |
2019-03-28 |
University Of Massachusetts |
NEW DUAL EXPRESSION VECTORS OF SOD1 AND USES THEREOF
|
|
EP3688021A4
(en)
|
2017-09-26 |
2021-12-29 |
University of Florida Research Foundation, Incorporated |
Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
|
|
CA3075656A1
(en)
|
2017-09-29 |
2019-04-04 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
WO2019079240A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
EA202090974A1
(ru)
|
2017-10-18 |
2020-08-05 |
Элпайн Иммьюн Сайенсиз, Инк. |
Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
|
|
EP3697449A1
(en)
|
2017-10-18 |
2020-08-26 |
REGENXBIO Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
|
WO2019079496A2
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION
|
|
US11723988B2
(en)
|
2017-10-20 |
2023-08-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector
|
|
JP7184894B2
(ja)
|
2017-11-27 |
2022-12-06 |
４ディー モレキュラー セラピューティクス インコーポレイテッド |
アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
|
|
KR20200104864A
(ko)
|
2017-11-30 |
2020-09-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
뮤코다당류증 iiib형에 대한 유전자 요법
|
|
JP7389744B2
(ja)
|
2017-11-30 |
2023-11-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉｉａ型のための遺伝子療法
|
|
MX2020006435A
(es)
|
2017-12-19 |
2021-02-09 |
Akouos Inc |
Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
|
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
KR102892243B1
(ko)
|
2018-01-17 |
2025-11-27 |
아드레나스 테라퓨틱스, 인코포레이티드 |
21-하이드록실라제 결핍을 위한 아데노-관련 바이러스 유전자 요법
|
|
WO2019152843A1
(en)
|
2018-02-01 |
2019-08-08 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
|
SG11202007942YA
(en)
*
|
2018-02-27 |
2020-09-29 |
Univ Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
|
AU2019227726B2
(en)
*
|
2018-02-27 |
2025-09-04 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (AAV) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
|
EP3765624A4
(en)
*
|
2018-03-16 |
2022-05-25 |
Research Institute at Nationwide Children's Hospital |
Increasing tissue specific gene delivery by capsid modification
|
|
SG11202009452WA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
|
JP7425738B2
(ja)
|
2018-04-03 |
2024-01-31 |
ギンコ バイオワークス インコーポレイテッド |
眼組織を標的とするウイルスベクター
|
|
JP2021519581A
(ja)
|
2018-04-03 |
2021-08-12 |
ストライドバイオ，インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
CA3093347A1
(en)
|
2018-04-05 |
2019-10-10 |
Genethon |
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
|
|
EP3775266A4
(en)
|
2018-04-05 |
2021-06-30 |
Massachusetts Eye and Ear Infirmary |
METHOD OF MANUFACTURING AND USING COMBINATIONAL BAR-CODED NUCLEIC ACID LIBRARIES WITH DEFINED VARIATION
|
|
JP7575273B2
(ja)
|
2018-04-16 |
2024-10-29 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法
|
|
US12419970B2
(en)
|
2018-04-18 |
2025-09-23 |
The Trustees Of Columbia University In The City Of New York |
Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
|
|
US12378576B2
(en)
|
2018-04-27 |
2025-08-05 |
Spacecraft Seven, Llc |
Gene therapy for CNS degeneration
|
|
WO2019212922A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
US12365865B2
(en)
|
2018-04-29 |
2025-07-22 |
Regenxbio Inc. |
Scalable clarification process for recombinant AAV production
|
|
CA3098871A1
(en)
|
2018-05-08 |
2019-11-14 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
|
EP3790627A2
(en)
|
2018-05-09 |
2021-03-17 |
BioMarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
|
BR112020022858A2
(pt)
|
2018-05-11 |
2021-02-23 |
Massachusetts Eye And Ear Infirmary |
tropismo específico hepático de vírus adeno-associado
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病を治療するための組成物および方法
|
|
CA3100066A1
(en)
|
2018-05-15 |
2019-11-21 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
CA3177467A1
(en)
|
2018-06-04 |
2019-12-12 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
US12070702B2
(en)
|
2018-06-14 |
2024-08-27 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
MX2021000443A
(es)
|
2018-07-12 |
2021-05-28 |
Spacecraft Seven Llc |
Vectores de terapia génica para el tratamiento de la enfermedad de danon.
|
|
SG11202100139VA
(en)
|
2018-07-17 |
2021-02-25 |
Neuromyon Inc |
Treatment of neuropathy with dna constructs expressing igf-1 isoforms
|
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
US20210277418A1
(en)
*
|
2018-08-03 |
2021-09-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
AU2019319976B2
(en)
|
2018-08-10 |
2025-08-14 |
Regenxbio Inc. |
Scalable method for recombinant AAV production
|
|
WO2020037303A1
(en)
|
2018-08-16 |
2020-02-20 |
The Regents Of The University Of California |
Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
|
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
SG11202102058UA
(en)
|
2018-08-30 |
2021-03-30 |
Tenaya Therapeutics Inc |
Cardiac cell reprogramming with myocardin and ascl1
|
|
EP3856913A4
(en)
|
2018-09-26 |
2022-10-26 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
JP7528066B2
(ja)
|
2018-09-28 |
2024-08-05 |
ボイジャー セラピューティクス インコーポレイテッド |
操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
|
|
SG11202103250UA
(en)
|
2018-10-01 |
2021-04-29 |
Toru Miyazaki |
Therapeutic agent for neurodegenerative disease
|
|
AR116569A1
(es)
|
2018-10-01 |
2021-05-19 |
Ultragenyx Pharmaceutical Inc |
Terapia génica para tratar la acidemia propiónica
|
|
PE20211596A1
(es)
|
2018-10-01 |
2021-08-18 |
Univ Pennsylvania |
Composiciones utiles para tratar la gangliosidosis gm1
|
|
EP3861010A1
(en)
|
2018-10-02 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
AU2019354793A1
(en)
*
|
2018-10-05 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding AAV production proteins
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2020081415A1
(en)
|
2018-10-15 |
2020-04-23 |
Regenxbio Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
EP3867389A1
(en)
|
2018-10-15 |
2021-08-25 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
KR20210082205A
(ko)
|
2018-10-22 |
2021-07-02 |
유니버시티 오브 로체스터 |
레트로바이러스 인테그라제-Cas9 융합 단백질을 이용한 유도된 비상동 DNA 삽입에 의한 게놈 편집
|
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
JP7329593B2
(ja)
|
2018-11-06 |
2023-08-18 |
カリディ・バイオセラピューティクス・インコーポレイテッド |
細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
|
|
CN113271982B
(zh)
|
2018-11-16 |
2024-07-30 |
摩大力斯医疗株式会社 |
通过靶向肌营养相关蛋白基因来治疗肌营养不良的方法
|
|
CN113891934A
(zh)
|
2018-11-21 |
2022-01-04 |
因达普塔治疗公司 |
扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
|
|
CA3120868A1
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
|
EP3886919A1
(en)
*
|
2018-11-30 |
2021-10-06 |
Novartis AG |
Aav viral vectors and uses thereof
|
|
CA3121177A1
(en)
|
2018-12-05 |
2020-06-11 |
Abeona Therapeutics Inc. |
Recombinant adeno-associated viral vector for gene delivery
|
|
WO2020140007A1
(en)
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
|
US12338450B2
(en)
|
2019-01-04 |
2025-06-24 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy constructs for treating Wilson disease
|
|
US12371698B2
(en)
|
2019-01-14 |
2025-07-29 |
University Of Rochester |
Targeted nuclear RNA cleavage and polyadenylation with CRISPR-Cas
|
|
US20220064671A1
(en)
|
2019-01-18 |
2022-03-03 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
KR20210130158A
(ko)
|
2019-01-31 |
2021-10-29 |
오레곤 헬스 앤드 사이언스 유니버시티 |
Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
|
|
KR20210131370A
(ko)
|
2019-02-22 |
2021-11-02 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스
|
|
EP3931334A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Compositions and methods to treat bietti crystalline dystrophy
|
|
JP2022520875A
(ja)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
|
|
PE20212072A1
(es)
|
2019-02-26 |
2021-10-26 |
Univ Pennsylvania |
Composiciones utiles en el tratamiento de la enfermedad de krabbe
|
|
CA3176660A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
AU2020241888A1
(en)
|
2019-03-21 |
2021-09-30 |
Ginkgo Bioworks, Inc. |
Recombinant adeno-associated virus vectors
|
|
EP3947427A1
(en)
|
2019-03-25 |
2022-02-09 |
Genethon |
Production of large-sized quasidystrophins using overlapping aav vectors
|
|
CA3135609A1
(en)
|
2019-04-01 |
2020-10-08 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
EP4667578A2
(en)
|
2019-04-03 |
2025-12-24 |
REGENXBIO Inc. |
Gene therapy for eye pathologies
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
HUE064411T2
(hu)
|
2019-04-11 |
2024-03-28 |
Regenxbio Inc |
Méretkizárásos kromatográfiás módszerek rekombináns adeno-asszociált víruskészítmények jellemzésére
|
|
CN113993552A
(zh)
|
2019-04-19 |
2022-01-28 |
再生生物股份有限公司 |
腺相关病毒载体制剂和方法
|
|
SG11202111414RA
(en)
|
2019-04-24 |
2021-11-29 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
EP3962536A1
(en)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
|
|
WO2020223236A1
(en)
*
|
2019-04-29 |
2020-11-05 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
BR112021021908A2
(pt)
|
2019-05-03 |
2022-02-01 |
Univ Pennsylvania |
Composições úteis no tratamento da leucodistrofia metacromática
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
WO2020232044A1
(en)
|
2019-05-14 |
2020-11-19 |
Biomarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
|
JP7565620B2
(ja)
|
2019-05-28 |
2024-10-11 |
株式会社モダリス |
Ｄｍｐｋ遺伝子を標的とした筋ジストロフィーの治療方法
|
|
WO2020243706A1
(en)
|
2019-05-30 |
2020-12-03 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
CA3144864A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
BR112021026866A2
(pt)
|
2019-07-02 |
2022-03-03 |
M6P Therapeutics |
Composições de vetor e métodos de seu uso para o tratamento de distúrbios do armazenamento lisossômico
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
AU2020311618B2
(en)
|
2019-07-11 |
2025-04-10 |
Centre Hospitalier Universitaire De Nantes |
Chemically-modified adeno-associated virus
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
WO2021016453A1
(en)
|
2019-07-23 |
2021-01-28 |
University Of Rochester |
Targeted rna cleavage with crispr-cas
|
|
WO2021021661A1
(en)
|
2019-07-26 |
2021-02-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
AU2020334462A1
(en)
|
2019-08-16 |
2022-02-24 |
Modalis Therapeutics Corporation |
Method for treating muscular dystrophy by targeting LAMA1 gene
|
|
US20220288235A1
(en)
*
|
2019-08-20 |
2022-09-15 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
|
MX2022002366A
(es)
|
2019-08-26 |
2022-07-19 |
Regenxbio Inc |
Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
WO2021041953A1
(en)
|
2019-08-30 |
2021-03-04 |
The Regents Of The University Of California |
Gene fragment overexpression screening methodologies, and uses thereof
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
CN114555814A
(zh)
|
2019-09-13 |
2022-05-27 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白-连接子聚合蛋白
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
CN114521143B
(zh)
|
2019-09-19 |
2025-03-14 |
吉尼松公司 |
减轻fkrp心脏毒性的基因治疗表达系统
|
|
US12436154B2
(en)
|
2019-09-20 |
2025-10-07 |
University Of Florida Research Foundation, Incorporated |
Detection of antibodies against RAN proteins from serum and tissue lysates
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
KR20220081365A
(ko)
|
2019-10-07 |
2022-06-15 |
리젠엑스바이오 인크. |
아데노-연관 바이러스 벡터 약제학적 조성물 및 방법
|
|
KR20220076510A
(ko)
|
2019-10-08 |
2022-06-08 |
트러스티스 오브 보스톤 칼리지 |
다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
|
|
CN115003820A
(zh)
|
2019-10-08 |
2022-09-02 |
爱科霍拉有限公司 |
用于眼部治疗的组合物和方法
|
|
EP4045093A4
(en)
|
2019-10-14 |
2024-02-07 |
Duke University |
Compositions comprising novel prokaryotic sodium channels and associated methods
|
|
KR20220083714A
(ko)
*
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
|
|
WO2021092300A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
EP4055034A4
(en)
*
|
2019-11-08 |
2024-05-29 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
JP2023503637A
(ja)
*
|
2019-11-28 |
2023-01-31 |
リジェネックスバイオ インコーポレイテッド |
マイクロジストロフィン遺伝子治療コンストラクト及びその使用
|
|
WO2021113767A1
(en)
*
|
2019-12-04 |
2021-06-10 |
Sangamo Therapeutics, Inc. |
Novel compositions and methods for producing recombinant aav
|
|
TW202129002A
(zh)
|
2019-12-09 |
2021-08-01 |
英商Ｕｃｌ商業有限責任公司 |
用於myh7關聯之心肌病之基因療法組合物及治療
|
|
EP4072595A1
(en)
|
2019-12-10 |
2022-10-19 |
Takeda Pharmaceutical Company Limited |
Adeno associated virus vectors for the treatment of hunter disease
|
|
KR20220128632A
(ko)
|
2019-12-31 |
2022-09-21 |
스완바이오 테라퓨틱스 리미티드 |
개선된 aav-abcd1 구축물 및 부신백질이영양증 (ald) 및/또는 부신척수신경병증 (amn)의 치료 또는 예방을 위한 용도
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
WO2021150570A1
(en)
|
2020-01-22 |
2021-07-29 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
|
AU2021214174A1
(en)
|
2020-01-29 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells
|
|
JP2023512043A
(ja)
|
2020-01-29 |
2023-03-23 |
レジェンクスバイオ インコーポレーテッド |
ムコ多糖症ｉｖａの治療
|
|
CA3165057A1
(en)
|
2020-02-02 |
2021-08-05 |
James M. Wilson |
Compositions useful for treating gm1 gangliosidosis
|
|
US20230078498A1
(en)
|
2020-02-07 |
2023-03-16 |
University Of Rochester |
Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
|
|
EP4100533A1
(en)
|
2020-02-07 |
2022-12-14 |
University of Rochester |
Ribozyme-mediated rna assembly and expression
|
|
BR112022015921A2
(pt)
|
2020-02-14 |
2022-10-04 |
Ultragenyx Pharmaceutical Inc |
Terapia gênica para tratar o transtorno de deficiência de cdkl5
|
|
US20230136699A1
(en)
|
2020-02-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene therapy for maple syrup urine disease
|
|
EP4114421A1
(en)
|
2020-03-02 |
2023-01-11 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
|
WO2022074464A2
(en)
|
2020-03-05 |
2022-04-14 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
CN115485289A
(zh)
|
2020-03-11 |
2022-12-16 |
宾夕法尼亚大学董事会 |
使用工程化的病毒颗粒进行基因递送的方法和组合物
|
|
WO2021188892A1
(en)
|
2020-03-19 |
2021-09-23 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
KR20220160069A
(ko)
|
2020-03-27 |
2022-12-05 |
유씨비 바이오파마 에스알엘 |
자율적 노브 도메인 펩티드
|
|
JP2023519344A
(ja)
|
2020-03-27 |
2023-05-10 |
ユニバーシティ オブ ロチェスター |
ＣＲＩＳＰＲ－Ｃａｓ１３ ｃｒＲＮＡアレイ
|
|
EP4127169A1
(en)
|
2020-03-27 |
2023-02-08 |
University of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
US20230131352A1
(en)
|
2020-04-01 |
2023-04-27 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
KR20220167324A
(ko)
|
2020-04-10 |
2022-12-20 |
솔라 바이오사이언시즈 엘엘씨 |
단백질 응집 장애의 치료를 위한 조성물 및 방법
|
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
JP2023522106A
(ja)
*
|
2020-04-20 |
2023-05-26 |
テナヤ セラピューティクス， インコーポレイテッド |
操作されたキャプシドを有するアデノ随伴ウイルス
|
|
EP4139439A1
(en)
|
2020-04-22 |
2023-03-01 |
Indapta Therapeutics, Inc. |
Natural killer (nk) cell compositions and methods for generating same
|
|
WO2021222168A2
(en)
|
2020-04-28 |
2021-11-04 |
Sola Biosciences Llc |
Compositions and methods for the treatment of tdp-43 proteinopathies
|
|
EP4125977A4
(en)
|
2020-05-05 |
2024-09-25 |
Duke University |
CROSS-SPECIES COMPATIBLE ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF
|
|
CN115803064A
(zh)
|
2020-05-12 |
2023-03-14 |
宾夕法尼亚州大学信托人 |
用于drg特异性降低转基因表达的组合物
|
|
AU2021271635A1
(en)
|
2020-05-12 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
EP4165194A2
(en)
|
2020-05-13 |
2023-04-19 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
PE20230767A1
(es)
|
2020-05-13 |
2023-05-09 |
Voyager Therapeutics Inc |
Redireccion del tropismo de las capsides de aav
|
|
CA3183171A1
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating slc26a4-associated hearing loss
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023529371A
(ja)
|
2020-06-05 |
2023-07-10 |
ソラ・バイオサイエンシズ・エルエルシー |
シヌクレイノパチーの処置のための組成物および方法
|
|
US20230220069A1
(en)
|
2020-06-17 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
JP2023530171A
(ja)
|
2020-06-19 |
2023-07-13 |
ジェネトン |
筋肉内及び心臓内でのｓｇｃｇの適切な発現を可能にする遺伝子療法発現系
|
|
US20230242905A1
(en)
*
|
2020-07-03 |
2023-08-03 |
Genethon |
Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping
|
|
WO2022010834A1
(en)
*
|
2020-07-07 |
2022-01-13 |
The Board Of Regents Of The University Of Texas System |
Adeno-associated virus vector for dwarf open reading frame
|
|
JP2023532806A
(ja)
|
2020-07-10 |
2023-07-31 |
ジェネトン |
新規の筋肉特異的プロモーター
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
EP4179097A1
(en)
|
2020-07-13 |
2023-05-17 |
The Trustees of The University of Pennsylvania |
Compositions useful for treatment of charcot-marie-tooth disease
|
|
EP4182455A1
(en)
|
2020-07-15 |
2023-05-24 |
University of Rochester |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
EP4189095A1
(en)
|
2020-07-27 |
2023-06-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CN115927398B
(zh)
*
|
2020-07-29 |
2024-11-19 |
北京三诺佳邑生物技术有限责任公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
JP2023539574A
(ja)
|
2020-08-17 |
2023-09-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
Ｓｈａｎｋ３遺伝子治療アプローチ
|
|
AR123288A1
(es)
|
2020-08-19 |
2022-11-16 |
Stridebio Inc |
Vectores de virus adenoasociados para el tratamiento del síndrome de rett
|
|
EP4200429A1
(en)
|
2020-08-24 |
2023-06-28 |
The Trustees of The University of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
JP2023540054A
(ja)
|
2020-08-26 |
2023-09-21 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｇｒｎ関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
|
|
CA3194019A1
(en)
|
2020-09-04 |
2022-03-10 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
JP2023545424A
(ja)
|
2020-10-07 |
2023-10-30 |
リジェネックスバイオ インコーポレイテッド |
ゲル製剤などの脈絡膜上投与用製剤
|
|
CA3198368A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
MX2023004035A
(es)
|
2020-10-07 |
2023-07-05 |
Regenxbio Inc |
Formulaciones para la administración supracoroidea tales como formulaciones de viscosidad alta.
|
|
JP2023545722A
(ja)
|
2020-10-07 |
2023-10-31 |
リジェネックスバイオ インコーポレイテッド |
遺伝子治療剤の眼送達のためのアデノ随伴ウイルス
|
|
IL301643A
(en)
|
2020-10-07 |
2023-05-01 |
Regenxbio Inc |
Gene therapy for ocular manifestations of CLN2 disease
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
KR20230118075A
(ko)
|
2020-10-09 |
2023-08-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
파브리병 치료를 위한 조성물 및 방법
|
|
US20230383313A1
(en)
|
2020-10-18 |
2023-11-30 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
|
EP4236975A1
(en)
*
|
2020-10-29 |
2023-09-06 |
The Trustees of The University of Pennsylvania |
Aav capsids and compositions containing same
|
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
JP7733110B2
(ja)
|
2020-11-02 |
2025-09-02 |
バイオマリン ファーマシューティカル インコーポレイテッド |
アデノ随伴ウイルスを濃縮するためのプロセス
|
|
CA3200401A1
(en)
|
2020-11-03 |
2022-05-12 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
MX2023006444A
(es)
|
2020-12-01 |
2023-08-10 |
Univ Pennsylvania |
Composiciones novedosas con motivos dirigidos a tejido específico y composiciones que los contienen.
|
|
IL303239A
(en)
|
2020-12-01 |
2023-07-01 |
Univ Pennsylvania |
Compositions and their uses for the treatment of Engelmann syndrome
|
|
CR20230228A
(es)
|
2020-12-01 |
2023-07-18 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
IL303614A
(en)
|
2020-12-16 |
2023-08-01 |
Regenxbio Inc |
Method of producing a recombinant adeno-associated virus particle
|
|
IL303959A
(en)
|
2020-12-23 |
2023-08-01 |
Pfizer |
Methods for purification of aav vectors by affinity chromatography
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
EP4271419A1
(en)
|
2020-12-29 |
2023-11-08 |
Akouos, Inc. |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
|
TW202241479A
(zh)
|
2020-12-30 |
2022-11-01 |
美商安迅生物製藥公司 |
遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
|
|
CN116981697A
(zh)
|
2021-01-14 |
2023-10-31 |
森迪生物科学公司 |
可分泌有效载荷调节
|
|
EP4281568A1
(en)
|
2021-01-21 |
2023-11-29 |
RegenxBio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
WO2022159871A1
(en)
*
|
2021-01-25 |
2022-07-28 |
Coda Biotherapeutics, Inc. |
Adeno-associated virus capsids and engineered ligand-gated ion channels for treating focal epilepsy and neuropathic pain
|
|
AU2022214429A1
(en)
|
2021-02-01 |
2023-09-14 |
Tern Therapeutics, Llc |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
WO2022169774A1
(en)
*
|
2021-02-02 |
2022-08-11 |
University Of Massachusetts |
Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
|
|
CA3206272A1
(en)
|
2021-02-05 |
2022-08-11 |
Carleton Proctor Goold |
Vectors comprising stuffer polynucleotide sequences
|
|
WO2022173847A2
(en)
*
|
2021-02-09 |
2022-08-18 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
WO2022173605A2
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
KR20230150836A
(ko)
|
2021-02-26 |
2023-10-31 |
다케다 야쿠힌 고교 가부시키가이샤 |
파브리병 치료를 위한 조성물 및 방법
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240191213A1
(en)
|
2021-03-19 |
2024-06-13 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
EP4320139A1
(en)
|
2021-04-05 |
2024-02-14 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
KR20230170022A
(ko)
|
2021-04-12 |
2023-12-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
척수 및 연수 근위축증(sbma) 치료에 유용한 조성물
|
|
AU2022261125A1
(en)
|
2021-04-23 |
2023-11-23 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
|
AR125406A1
(es)
|
2021-04-23 |
2023-07-12 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
|
|
JP2024515902A
(ja)
|
2021-04-26 |
2024-04-10 |
アレクシオン ファーマ インターナショナル オペレーションズ リミテッド |
組織向性が改善されたアデノ随伴ウイルスベクターカプシド
|
|
TW202309293A
(zh)
|
2021-04-26 |
2023-03-01 |
美商銳進科斯生物股份有限公司 |
用於治療肌縮蛋白症(dystrophinopathy)之微小肌縮蛋白基因療法給藥
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
EP4337267A1
(en)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
CN117813314A
(zh)
*
|
2021-06-08 |
2024-04-02 |
Nf2治疗公司 |
用于治疗神经纤维瘤疾患的组合物和方法
|
|
EP4355888A4
(en)
*
|
2021-06-18 |
2025-07-02 |
Dyno Therapeutics Inc |
CAPSID VARIANTS AND METHODS OF USE THEREOF
|
|
MX2023015329A
(es)
|
2021-06-22 |
2024-01-23 |
Pfizer |
Produccion de vector de virus adeno-asociado en celulas de insecto.
|
|
US20240287493A1
(en)
*
|
2021-06-24 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
WO2023283649A1
(en)
|
2021-07-08 |
2023-01-12 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
EP4373947A1
(en)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
WO2023004407A2
(en)
*
|
2021-07-23 |
2023-01-26 |
Duke University |
Adeno-associated virus compositions and methods of use thereof
|
|
TW202320836A
(zh)
|
2021-07-30 |
2023-06-01 |
宮崎徹 |
缺血性疾病之治療劑
|
|
EP4384193A2
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
US20240425820A1
(en)
|
2021-08-11 |
2024-12-26 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
JP2024534772A
(ja)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー，インコーポレイテッド |
同種異系細胞療法用の遺伝子改変細胞
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
EP4392570A4
(en)
*
|
2021-08-25 |
2025-07-16 |
Canbridge Pharmaceuticals Inc |
AAV PARTICLES COMPRISING A LIVER-TROPIC CAPSID PROTEIN AND AN ACID ALPHA-GLUCOSIDASE (GAA) AND THEIR USE FOR TREATING POMPE DISEASE
|
|
KR20240073025A
(ko)
*
|
2021-08-25 |
2024-05-24 |
캔브리지 파마슈티컬스, 인크. |
간-향성 캡시드 단백질 및 알파-갈락토시다제를 포함하는 aav 입자 및 파브리 질환을 치료하기 위한 이의 용도
|
|
EP4396237A4
(en)
|
2021-08-31 |
2025-11-19 |
Scout Bio Inc |
Antigen-binding molecules and their uses
|
|
US20250223376A1
(en)
|
2021-09-20 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
PE20241065A1
(es)
|
2021-09-30 |
2024-05-13 |
Akouos Inc |
Composiciones y metodos para el tratamiento de la perdida de audicion asociada a kcnq4
|
|
WO2023056399A1
(en)
|
2021-10-02 |
2023-04-06 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
US20230151372A1
(en)
*
|
2021-10-07 |
2023-05-18 |
Academia Sinica |
Composition and Method of Treatment for Heart Protection and Regeneration
|
|
US20250001006A1
(en)
|
2021-10-07 |
2025-01-02 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
EP4413019A2
(en)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
EP4413024A2
(en)
|
2021-10-08 |
2024-08-14 |
SOLA Biosciences LLC |
Compositions and methods for the treatment of proteopathies
|
|
WO2023060264A1
(en)
|
2021-10-08 |
2023-04-13 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
|
JP2024537178A
(ja)
|
2021-10-08 |
2024-10-10 |
ソラ・バイオサイエンシズ・エルエルシー |
ｐ５３媒介性癌の処置のための組成物および方法
|
|
JP2024539012A
(ja)
|
2021-10-12 |
2024-10-28 |
ブリッジバイオ ジーン セラピー エルエルシー |
白質ジストロフィーを治療するための方法及び組成物
|
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
|
EP4423285A1
(en)
|
2021-10-28 |
2024-09-04 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
MX2024004936A
(es)
|
2021-11-02 |
2024-05-08 |
Voyager Therapeutics Inc |
Variantes de capsides de aav y sus usos.
|
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4433169A1
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
TW202325850A
(zh)
|
2021-11-29 |
2023-07-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Aadc、gdnf多核苷酸及其用於治療帕金森病
|
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
WO2023114901A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the production of adeno-associated virus
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
TW202338086A
(zh)
|
2022-01-10 |
2023-10-01 |
賓州大學委員會 |
有用於治療異染性白質失養症之組成物
|
|
TW202340467A
(zh)
|
2022-01-10 |
2023-10-16 |
賓州大學委員會 |
有用於治療c9orf72介導之病症之組成物及方法
|
|
WO2023135316A1
(en)
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
Gene therapy composition and treatment for dystrophin-related cardiomyopathy
|
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
|
EP4469585A2
(en)
|
2022-01-25 |
2024-12-04 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
EP4469584A1
(en)
|
2022-01-25 |
2024-12-04 |
The Trustees of The University of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
WO2023150142A1
(en)
|
2022-02-02 |
2023-08-10 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
IL315000A
(en)
|
2022-02-17 |
2024-10-01 |
Sana Biotechnology Inc |
Engineered cd47 proteins and uses thereof
|
|
TW202342526A
(zh)
|
2022-02-21 |
2023-11-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Ｖｅｇｆ結合分子及其醫藥用途
|
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
EP4493226A1
(en)
|
2022-03-13 |
2025-01-22 |
RegenxBio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
EP4504950A1
(en)
|
2022-04-01 |
2025-02-12 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
|
KR20250007064A
(ko)
|
2022-04-06 |
2025-01-13 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Her2 양성 전이성 유방암 및 기타 암을 치료하기 위한 조성물 및 방법
|
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
EP4508222A1
(en)
|
2022-04-11 |
2025-02-19 |
Centre National de la Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
|
EP4508062A1
(en)
|
2022-04-11 |
2025-02-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
EP4518973A1
(en)
|
2022-05-03 |
2025-03-12 |
RegenxBio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025518052A
(ja)
*
|
2022-05-24 |
2025-06-12 |
ケイト セラピューティクス， インコーポレイテッド |
Ｘｌｍｔｍを処置するための組成物
|
|
CA3257081A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
VAA CAPSIDE VARIANTS AND THEIR USES
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
CN119731321A
(zh)
|
2022-06-24 |
2025-03-28 |
图恩疗法股份有限公司 |
通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法
|
|
CA3259902A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
CA3259982A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
|
|
TW202424201A
(zh)
|
2022-07-06 |
2024-06-16 |
美商航海家醫療公司 |
Ａａｖ殼體變異體及其用途
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
AU2023320453A1
(en)
|
2022-08-03 |
2025-02-06 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
JP2025527658A
(ja)
|
2022-08-24 |
2025-08-22 |
リジェネックスバイオ インコーポレイテッド |
組換えアデノ随伴ウイルス及びその使用
|
|
JP2025529884A
(ja)
|
2022-08-25 |
2025-09-09 |
武田薬品工業株式会社 |
ファブリー病の治療に使用するための組成物
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CA3267804A1
(en)
|
2022-09-22 |
2024-03-28 |
Dinaqor Ag |
TREATMENT OF CARDIOMYOPATHY USING AAV GENE THERAPY VECTORS
|
|
UY40442A
(es)
|
2022-09-22 |
2024-02-15 |
Biomarin Pharm Inc |
Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
|
|
IL319873A
(en)
|
2022-09-30 |
2025-05-01 |
Regenxbio Inc |
Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
|
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
|
JP2025534666A
(ja)
|
2022-10-11 |
2025-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
EP4634394A2
(en)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
CN120752339A
(zh)
|
2023-01-06 |
2025-10-03 |
国家医疗保健研究所 |
静脉内施用用于治疗疼痛的反义寡核苷酸
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024149844A1
(en)
|
2023-01-12 |
2024-07-18 |
Nantes Université |
Chemically-modified adeno-associated virus
|
|
WO2024163747A2
(en)
|
2023-02-02 |
2024-08-08 |
University Of Rochester |
Competitive replacement of glial cells
|
|
WO2024163979A2
(en)
*
|
2023-02-02 |
2024-08-08 |
Codexis, Inc. |
Engineered aav polypeptides
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4665743A2
(en)
|
2023-02-17 |
2025-12-24 |
Biogen MA Inc. |
Rgd-containing peptides for delivering payloads
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
WO2024196855A2
(en)
|
2023-03-17 |
2024-09-26 |
University Of Rochester |
Ribozyme-mediated rna assembly and expression
|
|
AU2024245299A1
(en)
*
|
2023-03-25 |
2025-09-25 |
Duke University |
Compositions comprising kidney-tropic aavs and methods of use thereof
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024220463A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav5 capsid with non-canonical amino acid incorporation and uses thereof
|
|
WO2024220389A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav2 variants and uses thereof
|
|
WO2024218192A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
|
|
WO2024218190A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Generation of adeno-associated virus capsid libraries for insect cells
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024229167A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2024229125A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
WO2024229302A1
(en)
|
2023-05-03 |
2024-11-07 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024229389A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
CN121079310A
(zh)
|
2023-05-03 |
2025-12-05 |
沃雅戈治疗公司 |
用于治疗与cdkl5缺乏相关的病症的组合物及方法
|
|
WO2024229425A1
(en)
|
2023-05-04 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
WO2025007046A1
(en)
|
2023-06-29 |
2025-01-02 |
The Trustees Of The University Of Pennsylvania |
Mutant aav with central nervous system targeting motifs and compositions containing same
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025017168A1
(en)
|
2023-07-19 |
2025-01-23 |
Genethon |
Novel optimized utrophin micro-genes
|
|
WO2025017169A1
(en)
|
2023-07-20 |
2025-01-23 |
Genethon |
Novel mididystrophins
|
|
WO2025035143A1
(en)
|
2023-08-10 |
2025-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of spinal muscular atrophy
|
|
WO2025042711A1
(en)
|
2023-08-18 |
2025-02-27 |
Eli Lilly And Company |
Engineered transferrin receptor binding peptides as well as methods of making and using the same
|
|
WO2025072604A1
(en)
|
2023-09-28 |
2025-04-03 |
University Of Rochester |
Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025080780A1
(en)
|
2023-10-10 |
2025-04-17 |
University Of Rochester |
Delivery and expression of prime editing crispr systems
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
WO2025096967A1
(en)
|
2023-11-02 |
2025-05-08 |
Biogen Ma Inc. |
Redirection of aav capsids for central nervous system targeting
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025171001A1
(en)
|
2024-02-06 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for improved production of aav viral vectors
|
|
WO2025188625A1
(en)
|
2024-03-03 |
2025-09-12 |
Passage Bio, Inc. |
Recombinant adeno-associated virus for treatment of neurodegenerative disorders
|
|
WO2025188755A1
(en)
|
2024-03-04 |
2025-09-12 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025207932A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids comprising anti-transferrin antibody domains
|
|
WO2025207948A1
(en)
|
2024-03-27 |
2025-10-02 |
Biogen Ma Inc. |
Aav capsids for targeting human transferrin receptor
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025242657A1
(en)
|
2024-05-21 |
2025-11-27 |
Shape Biopharmaceuticals Ag |
Lipopeptide building blocks and aggregates
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|